Evidence map›Paper›PMID 31043528›Full record

ArticleJournal of virology2019

CD4 Expression and Env Conformation Are Critical for HIV-1 Restriction by SERINC5.

Xihe Zhang, Jing Shi, Xusheng Qiu, Qingqing Chai, Dylan A Frabutt, Richard C Schwartz, Yong-Hui Zheng

Open access · bronzeAbstract read
In one paragraph

Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.

0numbers the graph read from it
0cells of the map it votes in
35citing papers in PubMed
4.3field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

35 citing papers in PubMed, 48 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. SERINC5 counters retroviruses and non-retroviruses.Frontiers in cellular and infection microbiology · 2024
    Review
  7. Review
  8. Article
  9. HIV-1 restriction by SERINC5.Medical microbiology and immunology · 2023
    Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Xihe ZhangDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Jing ShiHarbin Veterinary Research Institute, CAAS-Michigan State University Joint Laboratory of Innate Immunity, State Key Laboratory of Veterinary Biotechnology, Chinese Academy of Agricultural Sciences, Harbin, China.
Xusheng QiuDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Qingqing ChaiDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Dylan A FrabuttDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Richard C SchwartzDepartment of Microbiology and Molecular Genetics, Michigan State University, East Lansing, Michigan, USA.
Yong-Hui ZhengHarbin Veterinary Research Institute, CAAS-Michigan State University Joint Laboratory of Innate Immunity, State Key Laboratory of Veterinary Biotechnology, Chinese Academy of Agricultural Sciences, Harbin, China zhengyo@msu.edu.ORCID 0000-0002-1098-7385
Michigan State University · USChinese Academy of Agricultural Sciences · CN

Funding

The role of SERINC5 in HIV-1 replicationR01AI145504 · NIAID · UNIVERSITY OF ILLINOIS AT CHICAGO · PI ZHENG, YONG-HUI · 2019 to 2023
$1.5M
To eradicate the HIV macrophage reservoirR01AI120189 · NIAID · MICHIGAN STATE UNIVERSITY · PI ZHENG, YONG-HUI · 2015 to 2017
$589k
Mechanism of HIV-1 Env Degradation by the ERAD pathwayR21AI122863 · NIAID · MICHIGAN STATE UNIVERSITY · PI ZHENG, YONG-HUI · 2016 to 2017
$426k
Mechanistic understanding of HIV-1 broad neutralizing antibody evolutionR21AI138707 · NIAID · MICHIGAN STATE UNIVERSITY · PI YU, KEFEI · 2018 to 2019
$426k
NIAID NIH HHS R01 AI120189NIAID NIH HHS R01 AI145504NIAID NIH HHS R21 AI122863NIAID NIH HHS R21 AI138707
6 · The paper itself

Abstract

Serine incorporator 5 (SERINC5) is a recently identified restriction factor that strongly blocks HIV-1 entry but is counteracted by Nef. Notably, tier 1 HIV-1 Env proteins are sensitive to SERINC5, whereas the majority of tier 2/3 Env proteins are resistant to SERINC5, when viruses are produced from CD4-negative cells and tested by a single-round replication assay. Here, we investigated the Env-dependent SERINC5 antiviral mechanism by comparing tier 1 NL Env with tier 3 AD8 Env proteins. We found that when NL and AD8 viruses were inoculated into CD4

Indexed as

CD4 AntigensCD4-Positive T-Lymphocytesenv Gene Products, Human Immunodeficiency VirusHIV-1Membrane ProteinsGene Expression RegulationHEK293 CellsHumansJurkat CellsProtein Structure, QuaternaryCD4 Antigensenv Gene Products, Human Immunodeficiency VirusMembrane ProteinsSERINC5 protein, humanCD4entryEnvHIV-1Nefrestriction factorSERINC5

Identifiers

PMID31043528
PMCPMC6600204
OpenAlexW2943343786

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.